MX357888B - Sales basicas de adicion de nitroxolina y usos de las mismas. - Google Patents

Sales basicas de adicion de nitroxolina y usos de las mismas.

Info

Publication number
MX357888B
MX357888B MX2015012720A MX2015012720A MX357888B MX 357888 B MX357888 B MX 357888B MX 2015012720 A MX2015012720 A MX 2015012720A MX 2015012720 A MX2015012720 A MX 2015012720A MX 357888 B MX357888 B MX 357888B
Authority
MX
Mexico
Prior art keywords
nitroxoline
addition salts
base addition
pharmaceutical compositions
methods
Prior art date
Application number
MX2015012720A
Other languages
English (en)
Other versions
MX2015012720A (es
Inventor
Ke Pan
Original Assignee
Asieris Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asieris Pharmaceutical Tech Co Ltd filed Critical Asieris Pharmaceutical Tech Co Ltd
Publication of MX2015012720A publication Critical patent/MX2015012720A/es
Publication of MX357888B publication Critical patent/MX357888B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Se describen sales basicas de adición novesdosa de nitroxolina con mejorada solubilidad mejorada y secreción incrementada de orina bajo condiciones fisiológicas; se describen también composiciones farmacéuticas y métodos de tratamiento usando las composiciones farmacéuticas; la presente invención se refiere a sales básicas de adición novedosa de nitroxolina que tienen solubilidad y estabilidad mejoradas en soluciones acuosas, en comparación con la nitroxolina u otras sales de nitroxolina; la presente invención se refiere también a composiciones farmacéuticas que comprenden las sales basicas de adición de nitroxolina, y a métodos de tratamiento o de prevención de enfermedades, trastornos y condiciones usando estas composiciones farmacéuticas.
MX2015012720A 2013-03-15 2014-03-17 Sales basicas de adicion de nitroxolina y usos de las mismas. MX357888B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790059P 2013-03-15 2013-03-15
PCT/US2014/030532 WO2014145723A1 (en) 2013-03-15 2014-03-17 Base addition salts of nitroxoline and uses thereof

Publications (2)

Publication Number Publication Date
MX2015012720A MX2015012720A (es) 2016-06-21
MX357888B true MX357888B (es) 2018-07-27

Family

ID=51538074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012720A MX357888B (es) 2013-03-15 2014-03-17 Sales basicas de adicion de nitroxolina y usos de las mismas.

Country Status (11)

Country Link
US (1) US9758484B2 (es)
EP (1) EP2970128B1 (es)
JP (1) JP6273349B2 (es)
KR (1) KR20160021077A (es)
CN (1) CN105228984B (es)
AU (2) AU2014232722B2 (es)
BR (1) BR112015022849B1 (es)
CA (1) CA2907338C (es)
ES (1) ES2766758T3 (es)
MX (1) MX357888B (es)
WO (1) WO2014145723A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617525A (zh) * 2016-03-31 2025-09-12 江苏亚虹医药科技股份有限公司 硝羟喹啉和其类似物与化学疗法和免疫疗法在癌症治疗中的组合用途
MX2021003724A (es) * 2018-09-29 2021-05-14 Jiangsu Yahong Meditech Co Ltd Profarmaco de nitroxolina y su uso.
CN112402388A (zh) * 2019-08-05 2021-02-26 江苏亚虹医药科技股份有限公司 一种用于治疗膀胱癌的口服固体制剂及其制备方法
US20230000853A1 (en) * 2019-12-31 2023-01-05 Jiangsu Yahong Meditech Co., Ltd. Pharmaceutical composition containing nitroxoline, nitroxoline tablet, preparation method therefor and use thereof
TW202144329A (zh) * 2020-03-30 2021-12-01 大陸商江蘇亞虹醫藥科技股份有限公司 硝羥喹啉前藥的晶型、含其的醫藥組成物及其製備方法和應用
CN111773193A (zh) * 2020-07-03 2020-10-16 江苏亚虹医药科技有限公司 含硝羟喹啉赖氨酸盐的药物组合物及其制备方法和用途
CN111960998A (zh) * 2020-08-03 2020-11-20 江苏亚虹医药科技有限公司 硝羟喹啉衍生物及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745834A (en) * 1953-02-09 1956-05-15 Phillips Petroleum Co Stabilization of certain vinyl-pyridines, vinyl quinolines and vinyl-isoquinolines
US2745832A (en) * 1954-03-08 1956-05-15 Nuodex Products Co Inc Metal quinolinolates and methods of making the same
US3872128A (en) 1972-03-08 1975-03-18 Union Carbide Corp Antimicrobial hydroxy quinoline, ethylene-acrylic polymer compositions
JPS5768831A (en) * 1980-10-17 1982-04-27 Fuji Photo Film Co Ltd Heat developable photosensitive material
JPS57101835A (en) * 1980-12-17 1982-06-24 Fuji Photo Film Co Ltd Thermodevelopable photosensitive material
US4329185A (en) * 1981-01-21 1982-05-11 Dso "Pharmachim" Method for the preparation of a biologically active polyamide net
US5242892A (en) 1984-07-27 1993-09-07 The Board Of Trustees Of The University Of Illinois Chlorophyll biosynthesis modulators
JPH03284734A (ja) * 1990-03-31 1991-12-16 Toshiba Corp 有機非線形光学材料
IT1317735B1 (it) * 2000-01-26 2003-07-15 Nicox Sa Sali di agenti antimicrobici.
US7511137B2 (en) * 2003-12-19 2009-03-31 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
DK1888761T3 (da) * 2005-05-11 2010-11-01 Eth Zuerich Rekombinante N-glycosylerede proteiner fra prokaryote celler
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
WO2010042163A2 (en) * 2008-10-06 2010-04-15 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
EP2435036A2 (en) * 2009-05-28 2012-04-04 Merck Patent GmbH Ammoniumcarboxylates
JP2010070557A (ja) * 2009-12-17 2010-04-02 Anacor Pharmaceuticals Inc 加水分解抵抗性ホウ素含有治療薬および使用法
EP2353599A1 (en) * 2010-01-28 2011-08-10 University of Ljubljana 8-hydroxyquinolines as inhibitors of cathepsin B
WO2013006105A1 (en) * 2011-07-07 2013-01-10 Telefonaktiebolaget L M Ericsson (Publ) A method in a base station of a communication system for making a handover decision, base station, computer programs, and computer program products

Also Published As

Publication number Publication date
HK1214589A1 (zh) 2016-07-29
ES2766758T3 (es) 2020-06-15
AU2017200820A1 (en) 2017-03-02
MX2015012720A (es) 2016-06-21
US9758484B2 (en) 2017-09-12
KR20160021077A (ko) 2016-02-24
CA2907338A1 (en) 2014-09-18
CN105228984B (zh) 2018-03-23
AU2014232722A1 (en) 2015-09-24
EP2970128A1 (en) 2016-01-20
BR112015022849A2 (pt) 2017-12-26
AU2014232722B2 (en) 2017-03-09
EP2970128B1 (en) 2019-12-04
BR112015022849B1 (pt) 2020-02-18
CA2907338C (en) 2019-09-17
CN105228984A (zh) 2016-01-06
EP2970128A4 (en) 2016-11-30
US20160031819A1 (en) 2016-02-04
WO2014145723A1 (en) 2014-09-18
JP6273349B2 (ja) 2018-01-31
JP2016514705A (ja) 2016-05-23

Similar Documents

Publication Publication Date Title
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
IN2015DN01156A (es)
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
IN2014DN09434A (es)
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2015010125A (es) Derivados de piridazinona-amidas.
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2014KN02601A (es)
MX2016002368A (es) Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1).
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
NZ719169A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MD20170011A2 (ro) Compuşi imidazopiridazinici
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
EA201591704A1 (ru) Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии

Legal Events

Date Code Title Description
FG Grant or registration